NDA 018956 · Ge Healthcare
Omnipaque 140
Iohexol · Injection, Injection, Oral, Rectal, Oral, Injection, Oral, Urethral · Radiographic Contrast Agent
NovelLast checked: Nov 20, 2026Latest source record: Oct 8, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1985
Dec 26, 1985
Approved uses
14
Original approval plus efficacy supplements
Registered trials
74
5 Phase 3, 10 recruiting
FAERS reports
8,472
6,838 serious, 503 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISKS ASSOCIATED WITH INTRATHECAL ADMINISTRATION OF OMNIPAQUE INJECTION 140 mg IODINE/mL and 350 mg IODINE/mL Use only the OMNIPAQUE iodine concentrations and presentations recommended for intrathecal procedure [see Dosage and Administration (2.2 , 2.8) ]. Intrathecal administration of OMNIPAQUE of a wrong iodine concentration, even if inadvertent, may cause death, convulsions, seizures, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, rhabdomyolysis, hyperthermia, and brain edema [see Warnings and Precautions (5.1) ]. WARNING: RISKS ASSOCIATED WITH INTRATHECAL ADMINISTRATION OF OMNIPAQUE INJECTION 140 and 350 mg IODINE/mL Use only the iodine concentrations and presentations recommended for intrathecal procedures. Intrathecal administration of a wrong iodine concentration, even if inadvertent, may cause death, convulsions, seizures,...
What it is approved for
From the label in effect Apr 28, 2026.
OMNIPAQUE is a radiographic contrast agent indicated for intrathecal, intra-arterial, intravenous, oral, rectal, intraarticular, and body cavity imaging procedures in adults and pediatric patients. ( 1 ) 1.1 Intrathecal Procedures ‡ OMNIPAQUE is indicated for: Myelography and computerized tomography (CT) myelography (lumbar, thoracic, cervical, total columnar) in adults and pediatric patients aged 2 weeks and older CT cisternography in adults and pediatric patients aged 2 weeks and older 1.2 Intra-arterial Procedures ‡ OMNIPAQUE is indicated for: Cardiac ventriculography in adults and pediatric patients Aortography including studies of aorta and its branches in adults and pediatric patients Selective coronary arteriography in adults Cerebral arteriography in adults Peripheral arteriography in adults Intra-arterial digital subtraction angiography (IA-DSA) of the head, neck, abdominal, renal, and peripheral vessels in adults Pulmonary angiography in pediatric patients 1.3 Intravenous Procedures ‡ OMNIPAQUE is indicated for: Excretory urography in adults and pediatric patients CT of the head and body in adults and pediatric patients Peripheral venography (phlebography) in adults Intravenous digital subtraction angiography (IV-DSA) of the head, neck, abdominal, renal, and peripheral vessels in adults 1.4 Oral or Rectal Procedures ‡ OMNIPAQUE is indicated for: Radiographic examination of the gastrointestinal (GI) tract by oral administration in adult patients and by oral or rectal administration in pediatric patients CT of the abdomen and pelvis by oral administration in adult and pediatric patients, in conjunction with intravenous administration of OMNIPAQUE 1.5 Intraarticular Procedures ‡ OMNIPAQUE is indicated for: Arthrography in adults 1.6 Body Cavity Procedures ‡...
Mechanism: The iodine atoms in iohexol provide attenuation of X-rays in direct proportion to the concentration of iohexol. Since concentration changes over time, iohexol provides time-dependent image contrast which may assist in visualizing body structures.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 13, 1993 Supplement 28 · Efficacy Review
- Nov 30, 1989 Supplement 26 · Efficacy
- Jul 28, 1989 Supplement 22 · Efficacy
- Jul 28, 1989 Supplement 23 · Efficacy
- Jun 30, 1989 Supplement 20 · Efficacy
- Jun 30, 1989 Supplement 21 · Efficacy
- Mar 31, 1989 Supplement 18 · Efficacy
- Nov 30, 1988 Supplement 17 · Efficacy
- Jul 29, 1988 Supplement 14 · Efficacy
- May 24, 1988 Supplement 15 · Efficacy
- Feb 1, 1988 Supplement 12 · Efficacy
- May 12, 1987 Supplement 9 · Efficacy
- Nov 26, 1986 Supplement 1 · Efficacy
- Dec 26, 1985 Original approval · Type 1 - New Molecular Entity
9 products under this application
- OMNIPAQUE 140 · IOHEXOL 30.2% · INJECTABLE, INJECTION · Prescription
- OMNIPAQUE 300 · IOHEXOL 64.7% · SOLUTION, INJECTION, ORAL, RECTAL · Prescription · TE AP
- OMNIPAQUE 180 · IOHEXOL 38.8% · SOLUTION, INJECTION, ORAL, RECTAL · Prescription
- OMNIPAQUE 9 · IOHEXOL 1.9% · SOLUTION, ORAL · Prescription
- OMNIPAQUE 210 · IOHEXOL 45.3% · INJECTABLE, INJECTION · Discontinued
- OMNIPAQUE 350 · IOHEXOL 75.5% · SOLUTION, INJECTION, ORAL · Prescription · TE AP
- OMNIPAQUE 240 · IOHEXOL 51.8% · SOLUTION, INJECTION, ORAL, RECTAL · Prescription
- OMNIPAQUE 12 · IOHEXOL 2.6% · SOLUTION, ORAL · Prescription
- OMNIPAQUE 70 · IOHEXOL 15.1% · SOLUTION, URETHRAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Iohexol" as an intervention, any sponsor and status, largest first.
- Chest CT Using Low-concentration Iodine Contrast MediaPivotal-lookingStatus unknown
Jung Im JungAcademic, hospital or other
NCT05967117 · 370 participants (planned) · Start Nov 24, 2023 · Primary completion Nov 2024
Drug: Iohexol (320mgI/mL) with 120kVp; Iohexol (320mgI/mL) with 100kVp and 2 more · For: Pulmonary Disease
Sites: Bucheon-si, South Korea; Yangsan, South Korea; Jeonju, South Korea · 6 sites in all
- Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent IohexolActive, not recruiting
NRG OncologyAcademic, hospital or other
NCT03997370 · 350 participants (planned) · Start Jan 15, 2020 · Primary completion Mar 14, 2028
Drug: Carboplatin; Iohexol · For: Malignant Solid Neoplasm
Sites: Tucson, Arizona; Fort Smith, Arkansas; Little Rock, Arkansas · 189 sites in all
Centre Hospitalier Universitaire de Saint EtienneAcademic, hospital or other
NCT02522338 · 300 participants · Start Feb 2011 · Primary completion Dec 2013
Drug: iohexol · For: HIV
Sites: Saint-Etienne, France
- Omnipaque Versus Gastroview as Oral Contrast for Abdominal and Pelvic CTPivotal-lookingCompleted
University of Alabama at BirminghamAcademic, hospital or other
NCT00478556 · 300 participants · Start Aug 2007 · Primary completion Mar 2009
Drug: Omnipaque; Gastroview · For: Healthy
Sites: Birmingham, Alabama
- Dosing Iodinated Contrast Media According to Lean vs. Total Body WeightPivotal-lookingCompleted
Nova Scotia Health AuthorityAcademic, hospital or other
NCT03415997 · 239 participants · Start Feb 21, 2018 · Primary completion Nov 9, 2018
Drug: Iohexol · For: Contrast Media Dosing
Sites: Halifax, Canada
MediBeaconIndustry
NCT02772276 · 234 participants · Start May 11, 2016 · Primary completion Aug 4, 2021
Drug: MB-102-- single dose of 4 µmol/kg; MB-102-- single dose of 130 mg and 3 more · For: Acute Kidney Injury
Sites: Edgewater, Florida; Orlando, Florida; St Louis, Missouri
- Comparison of Vascular Access for Radial and Femoral Completion of Diagnostic Cardiac CatheterizationPivotal-lookingCompleted
Centro Cardiológico del Caribe, ColumbiaAcademic, hospital or other
NCT01984411 · 220 participants · Start Jan 2013 · Primary completion Jan 2013
Drug: Omnipaque · For: Ischemic Heart Diseases
Sites: Barranquilla, Colombia
- A Study of LY4515100 in Healthy ParticipantsPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07339722 · 209 participants (planned) · Start Jan 15, 2026 · Primary completion Mar 2027
Drug: LY4515100 via SAD; LY4515100 via MAD and 12 more · For: Healthy
Sites: Dallas, Texas; Madison, Wisconsin
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- urticaria1,021
- pruritus929
- dyspnoea799
- sneezing630
- erythema586
- nausea538
- vomiting494
- rash430
- chills360
- cough338
- anaphylactic reaction322
- acute kidney injury299
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 7 |
| 2005 | 10 |
| 2006 | 5 |
| 2007 | 7 |
| 2008 | 11 |
| 2009 | 6 |
| 2010 | 13 |
| 2011 | 17 |
| 2012 | 175 |
| 2013 | 370 |
| 2014 | 699 |
| 2015 | 601 |
| 2016 | 578 |
| 2017 | 697 |
| 2018 | 576 |
| 2019 | 550 |
| 2020 | 577 |
| 2021 | 489 |
| 2022 | 491 |
| 2023 | 542 |
| 2024 | 617 |
| 2025 | 778 |
| 2026 | 656 |
Recalls
3 FDA enforcement reports for this application.
Mar 24, 2026 · Class II · Ongoing
Presence of particulate matter
Mar 24, 2026 · Class II · Ongoing
Presence of particulate matter
Oct 29, 2018 · Class II · Terminated
Defective Container: vial defect was identified that could potentially impact the container closure and result in a lack of sterility assurance and/or the potential for glass particles.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Adjunct-to-insulin therapy using SGLT2 inhibitors in youth with type 1 diabetes: a randomized controlled trial.
Mahmud FH, Bjornstad P, Clarson C, et al. · Nat Med 2025 · Randomized Controlled Trial
- Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes.
Doria A, Galecki AT, Spino C, et al. · N Engl J Med 2020 · Multicenter Study, Randomized Controlled Trial
- Clinical validation of the novel fluorescent glomerular filtration rate tracer agent relmapirazin (MB-102).
Dorshow RB, Debreczeny MP, Goldstein SL, et al. · Kidney Int 2024 · Clinical Trial, Phase II, Comparative Study
- Alkaline phosphatase to treat ischaemia-reperfusion injury in living-donor kidney transplantation: APhIRI I feasibility pilot study.
Steenvoorden TS, van Duin RE, Rood JAJ, et al. · Br J Clin Pharmacol 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Relative Conspicuity of Gadolinium-Based Contrast Agents in Interventional Pain Procedures.
Maus TP, Schueler BA, Magnuson DJ, et al. · Pain Med 2017 · Controlled Clinical Trial
- A Novel Method for Rapid Bedside Measurement of GFR.
Rizk DV, Meier D, Sandoval RM, et al. · J Am Soc Nephrol 2018 · Clinical Trial, Phase II, Comparative Study
Sponsor: Ge Healthcare · Also marketed as Omnipaque 300, Omnipaque 180, Omnipaque 9, Omnipaque 210, Omnipaque 350
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.